Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) use among diabetic patients recovered from dialysis-requiring AKI was associated with a lower risk of ESKD and all-cause mortality [28]. The gene discussed is ACE; the disease is acute kidney injury.